Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PF-562,271

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Focal adhesion kinase (FAK) is considered as an attractive target for oncology. A series of F-18 labeled 5-bromo-N2-(4-(2-fluoro… Expand
2015
2015
Glioblastoma is one of the most aggressive and fatal brain cancers due to the highly invasive nature of glioma cells. Microglia… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2015
2015
Integrins play crucial roles in epithelial adhesion, proliferation, wound healing and cancer. In the epidermis, the roles of many… Expand
  • table 1
  • figure 1.3
  • table 2.1
  • table 2.2
  • table 2.3
2014
2014
Ovarian clear cell carcinoma (OCCC) displays a higher resistance to first line chemotherapy, requiring the development of new… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2013
2013
The focal adhesion kinase inhibitor, PF-562,271, is currently in clinical development for cancer, however it is not known how PF… Expand
Highly Cited
2012
Highly Cited
2012
Focal adhesion kinase (FAK) is upregulated in several epithelial tumours and there has been considerable interest in developing… Expand
Highly Cited
2011
Highly Cited
2011
Current therapies for pancreatic ductal adenocarcinoma (PDA) target individual tumor cells. Focal adhesion kinase (FAK) is… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2010
2010
Focal adhesion kinase (FAK) is essential in regulating integrin signaling pathways responsible for cell survival and… Expand
Highly Cited
2009
Highly Cited
2009
Experimental Design: To investigate the anti-tumor effect of sunitinib and FAK/Pyk2 tyrosine kinase inhibitor (PF-562,271… Expand
Highly Cited
2008
Highly Cited
2008
Cancer cells are characterized by the ability to grow in an anchorage-independent manner. The activity of the nonreceptor… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2